In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia

Viviana Cavalca, Bianca Rocca, Isabella Squellerio, Alfredo Dragani, Fabrizio Veglia, Francesca Pagliaccia, Benedetta Porro, Silvia Stella Barbieri, Elena Tremoli, Carlo Patrono

Research output: Contribution to journalArticle

Abstract

Essential thrombocythaemia (ET) is characterised by enhanced platelet generation and thrombosis. Once daily (od) aspirin incompletely inhibits platelet thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET patients on entericcoated (EC) aspirin 100 mg od, by measuring its urinary metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin regimen, demonstrating its vascular safety for future trials.

Original languageEnglish
Pages (from-to)118-127
Number of pages10
JournalThrombosis and Haemostasis
Volume112
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Essential Thrombocythemia
Epoprostenol
Aspirin
Blood Platelets
Thromboxane A2
Cross-Over Studies
Blood Vessels
Healthy Volunteers
Thrombosis

Keywords

  • Aspirin
  • Essential thrombocythaemia
  • Platelets
  • Prostacyclin
  • Thromboxane

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. / Cavalca, Viviana; Rocca, Bianca; Squellerio, Isabella; Dragani, Alfredo; Veglia, Fabrizio; Pagliaccia, Francesca; Porro, Benedetta; Barbieri, Silvia Stella; Tremoli, Elena; Patrono, Carlo.

In: Thrombosis and Haemostasis, Vol. 112, No. 1, 2014, p. 118-127.

Research output: Contribution to journalArticle

@article{8bb64b05279b4397ad112d4bba20ec40,
title = "In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia",
abstract = "Essential thrombocythaemia (ET) is characterised by enhanced platelet generation and thrombosis. Once daily (od) aspirin incompletely inhibits platelet thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET patients on entericcoated (EC) aspirin 100 mg od, by measuring its urinary metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin regimen, demonstrating its vascular safety for future trials.",
keywords = "Aspirin, Essential thrombocythaemia, Platelets, Prostacyclin, Thromboxane",
author = "Viviana Cavalca and Bianca Rocca and Isabella Squellerio and Alfredo Dragani and Fabrizio Veglia and Francesca Pagliaccia and Benedetta Porro and Barbieri, {Silvia Stella} and Elena Tremoli and Carlo Patrono",
year = "2014",
doi = "10.1160/TH13-10-0844",
language = "English",
volume = "112",
pages = "118--127",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia

AU - Cavalca, Viviana

AU - Rocca, Bianca

AU - Squellerio, Isabella

AU - Dragani, Alfredo

AU - Veglia, Fabrizio

AU - Pagliaccia, Francesca

AU - Porro, Benedetta

AU - Barbieri, Silvia Stella

AU - Tremoli, Elena

AU - Patrono, Carlo

PY - 2014

Y1 - 2014

N2 - Essential thrombocythaemia (ET) is characterised by enhanced platelet generation and thrombosis. Once daily (od) aspirin incompletely inhibits platelet thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET patients on entericcoated (EC) aspirin 100 mg od, by measuring its urinary metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin regimen, demonstrating its vascular safety for future trials.

AB - Essential thrombocythaemia (ET) is characterised by enhanced platelet generation and thrombosis. Once daily (od) aspirin incompletely inhibits platelet thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET patients on entericcoated (EC) aspirin 100 mg od, by measuring its urinary metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin regimen, demonstrating its vascular safety for future trials.

KW - Aspirin

KW - Essential thrombocythaemia

KW - Platelets

KW - Prostacyclin

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=84903772446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903772446&partnerID=8YFLogxK

U2 - 10.1160/TH13-10-0844

DO - 10.1160/TH13-10-0844

M3 - Article

C2 - 24671522

AN - SCOPUS:84903772446

VL - 112

SP - 118

EP - 127

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -